Therabel

What Therabel does

Therabel is a privately-owned European pharmaceutical company founded in 1945 and headquartered in Forest, Belgium, with 101–250 employees and a 2019 group turnover of €59.1 million. The company operates a partnership-driven commercialization model, in-licensing or partnering pharmaceutical products (both prescription and OTC) from other manufacturers and providing the full European market access stack — regulatory registration, pricing and reimbursement, and dual-channel sales and marketing coverage at both hospital specialist and primary care/retail levels — in exchange for product commercialization rights.

Its portfolio spans six prescription therapeutic franchises — Cardiology (pulmonary arterial hypertension, angina, heart failure prevention), Pain (the full WHO pain ladder from NSAIDs through tramadol to fentanyl), Supportive Care (oncology and HIV secondary conditions), Respiratory (COPD, allergic rhinitis, cough/cold), Urology (BPH, interstitial cystitis), and Gastroenterology (reflux, constipation, diarrhea, biliary dysfunction) — plus OTC categories covering vitamins and minerals, cough and cold, and gastroenterology. There is no proprietary technology platform; the underlying capability is commercial and regulatory execution across fragmented European markets rather than a technology moat.

Therabel maintains direct commercial presence in France, Belgium, and the Grand Duchy of Luxembourg through field sales teams, while reaching 18 additional countries (predominantly across francophone Africa, plus Lebanon, Cambodia, and Switzerland) through local commercialization partners. The revenue model is best characterized as licensing, distribution, and co-promotion royalties combined with direct product sales in core markets. The corporate group includes wholly-owned manufacturing (Therabel Industries, France, 1992), global supply management (Therabel Pharmaceuticals Ltd, Ireland, 1999), and regional affiliates in the Netherlands (2007) and Germany (2010), with historical acquisitions including Lucien Pharma (France, 1991), Gienne Pharma (Italy, 1997), and Javelin Pharmaceuticals UK (2009).

Name

Therabel

Legal name

THERABEL INTERNATIONAL SERVICES SA/NV

Website

https://therabel.com

Company type

Private

Founded year

1945

Operating status

Operating

Headcount range

101–250 employees

Short description

Therabel is a privately-owned Belgian pharmaceutical company founded in 1945 that commercializes partnered Rx and OTC products across Europe via licensing, distribution, and co-promotion agreements, with direct sales in France, Belgium, and Luxembourg and a partner network spanning 18 additional countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Forest

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Pharmaceutical product sales: Therabel generates revenue through commercialization of partnered pharmaceutical products (Rx and OTC), medical devices, diagnostic solutions, and food supplements. The company operates on a partnership-based model where they provide regulatory support, market access, and sales & marketing activities in exchange for product rights.

Go-to-market motion2 records

Distribution channels2 records

Core offering

Therabel is a partnership-driven pharmaceutical company that commercializes a portfolio of specialty prescription drugs and OTC products across cardiology, pain, supportive care, respiratory, urology, and gastroenterology therapeutic areas. The company provides other pharmaceutical firms with a full European market access service spanning product registration, pricing and reimbursement, and sales & marketing execution at both hospital specialist and primary care levels. Revenue is generated through direct product sales, licensing, and royalty arrangements on partnered and acquired products.

Product overview

Therabel is a privately-owned pharmaceutical company established in 1945, operating a partnership-driven business model focused on regulatory support, market access, and sales & marketing activities across Europe. The company offers a portfolio of specialty care and primary care pharmaceutical drugs spanning six prescription therapeutic franchises (Cardiology, Pain, Supportive Care, Respiratory, Urology, and Gastroenterology) along with OTC products including Vitamins and Minerals, Cough & Cold, and Gastroenterology categories. Products are commercialized through partnerships, distribution agreements, joint-ventures, co-marketing, and co-promotion arrangements with other pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Cardiology franchise
• Pain franchise
• Supportive Care franchise
• Respiratory franchise
• Urology franchise
• Gastroenterology franchise
• Vitamins and Minerals (OTC)
• Cough & Cold (OTC)
• Gastroenterology OTC

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Various Pharmaceutical PartnerscoreStrategic or Co-development PartnerTherabel grows its products portfolio mostly through partnerships with other pharmaceutical companies on new, close-to-market or marketed products. They establish long-term partnerships to maximize product potential through ethical and creative promotional approaches. Partnership types include European-wide product licenses, distribution agreements, Joint-Ventures, co-marketing agreements, and co-promotion agreements. Most partners renew their collaboration due to high satisfaction levels.

Scale indicators4 records

Recent moves11 records

Expansion highlights3 records

Direct peers

• Servier: Servier is a French, privately-owned independent pharmaceutical company with broad therapeutic area coverage and a similar European commercial footprint. Both operate as independent mid-sized European pharma groups prioritizing partnership-based growth over scale-driven generics competition.
• Norgine: Norgine is a European specialty pharma with a partnership-driven model and overlapping therapeutic focus in gastroenterology. Both companies operate as mid-sized, partnership-led European players without primary care mass-market exposure.
• Vifor Pharma: Vifor Pharma is a Swiss specialty pharma with European-wide commercial presence and a partnership-driven portfolio model. Both companies pursue selected therapeutic franchises and rely on in-licensing to extend their offering.
• Helsinn: Helsinn is a Swiss privately-owned specialty pharma focused on supportive care in oncology—a direct overlap with one of Therabel's key Rx franchises. Both companies pursue licensing-based commercial models targeting European specialty hospital channels.
• Almirall: Almirall is a Spanish specialty pharma company with a comparable European partnership and licensing model. Both companies operate as mid-sized European specialty players focused on selected therapeutic areas and cross-border commercialization partnerships.
• Faes Farma: Faes Farma is a Spanish specialty pharma and OTC player with overlapping therapeutic areas (gastroenterology, respiratory) and a partnership-driven European strategy. Both companies balance prescription specialty with OTC categories.
• STADA Arzneimittel AG: STADA is a European-focused generics and specialty pharma company with a similar partnership-driven, multi-country commercialization model. Both companies compete in the European specialty and OTC segments and rely on in-licensing to round out their portfolios.
• Grünenthal: Grünenthal is a privately-held German specialty pharma with a strong Pain franchise spanning the WHO pain ladder, directly overlapping with Therabel's Pain portfolio. Both companies also pursue licensing-driven portfolio expansion in Europe.
• Recordati: Recordati is an Italian specialty pharma group with a similar European multi-country model and broad therapeutic coverage (cardiology, urology, gastroenterology, pain). Both companies target specialty care via partnerships and selective M&A across European markets.

Broad incumbents

• Ipsen: Ipsen is a larger French specialty pharma group with overlapping therapeutic interests (urology, oncology supportive care, gastroenterology) and a broader portfolio. It represents the scaled European specialty pharma archetype Therabel operates within but does not match in size.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/therabel

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Therabel